BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

NCT00962611 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Copanlisib (Aliqopa, BAY80-6946)

Sponsor

Bayer